Sdi Limited

SDI.ASX

Health Care

Manufacture and distribution of amalgam and composite restorative materials, other dental materials, and product research and development.

Latest Earnings

Appendix 4D Dcember 2025

27 February 2026

Revenue
$52.93
+2.7% YoY
NPAT
$3.75
-2.0% YoY
EPS
$0.03
Dividend
$0.02

SDI Limited's H1 FY26 results show modest revenue growth of 2.7% to $52.9M, driven by strong Australian and Middle Eastern markets, but normalised NPAT declined 2.0% to $3.75M after adjusting for a $0.5M doubtful debt provision. Gross margins expanded 210 bps to 65.6% on operational efficiencies and favourable FX, though Amalgam sales collapsed 23.1% due to EU regulatory bans and market decline, partially offset by Aesthetics growth. Management guidance remains cautious with major capital investments planned ($26M facility expansion commencing April 2026) and a potential acquisition in advanced discussions. Key points: Gross margin expanded significantly by 210 bps to 65.6% driven by operational efficiencies, product mix shift towards higher-margin Aesthetics, and favourable currency movements; Aesthetics product category shows strong growth of 4.5% in local currency across all regions; 'Stela' Amalgam replacement product positioned for wider aesthetic market penetration; Australian market momentum strong, up 11.9% in local currency with Middle Eastern direct exports driving growth of 10.2% regionally

Recent Announcements

27 Feb 2026 Actual Results Neutral

Appendix 4D Dcember 2025

SDI Limited's H1 FY26 results show modest revenue growth of 2.7% to $52.9M, driven by strong Australian and Middle Eastern markets, but normalised NPAT declined 2.0% to $3.75M after adjusting for a $0.5M doubtful debt provision. Gross margins expanded 210 bps to 65.6% on operational efficiencies and favourable FX, though Amalgam sales collapsed 23.1% due to EU regulatory bans and market decline, partially offset by Aesthetics growth. Management guidance remains cautious with major capital investments planned ($26M facility expansion commencing April 2026) and a potential acquisition in advanced discussions. Key points: Gross margin expanded significantly by 210 bps to 65.6% driven by operational efficiencies, product mix shift towards higher-margin Aesthetics, and favourable currency movements; Aesthetics product category shows strong growth of 4.5% in local currency across all regions; 'Stela' Amalgam replacement product positioned for wider aesthetic market penetration; Australian market momentum strong, up 11.9% in local currency with Middle Eastern direct exports driving growth of 10.2% regionally

Get real-time alerts for SDI

Receive AI-powered earnings summaries and instant notifications when Sdi Limited releases results.

Register Free